Vandetanib

drugbox
IUPAC_name = "N"-(4-bromo-2-fluoro-phenyl)-6-methoxy-7-
[(1-methyl-4-piperidyl)methoxy] quinazolin-4-amine

---

CAS_number = 443913-73-3
ATC_prefix =
ATC_suffix =
PubChem = 3081361
DrugBank =
C = 22 | H = 24 | Br = 1 | F = 1 | N = 4 | O = 2
molecular_weight = 475.354 g/mol
bioavailability =
protein_bound =
metabolism =
elimination_half-life = 5 days (mean)
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category =
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration = Oral

Vandetanib (rINN, proposed trade name Zactima), also known as ZD6474, is a medication currently undergoing clinical trials as a potential targeted treatment for non–small-cell lung cancer. It is an antagonist of the vascular endothelial growth factor receptor (VEGFR) and the epidermal growth factor receptor (EGFR).

Vandetanib is being developed by AstraZeneca.

External links

* [http://www.cancerline.com/vandetanib/ Cancerline.com: Vandetanib Information for Physicians]
* [http://www.AZ-Trials.com AZ-Trials.com: AstraZeneca Clinical Trials Patient Recruiting (US)]